News


All series


All News

The approval of a biologics license application (BLA) for epoetin hospira (Retacrit), an epoetin alfa (Epogen/Procrit) biosimilar manufactured by Hospira, was recommended for approval by the FDA’s Oncologic Drugs Committee voted (ODAC) 14-1 today.